3.315

9.92% -0.365

After Hours: 3.32 0.005 +0.15%

Pulmonx Corp (LUNG)

Overview News Price History Option Chain Financials Discussions Forecast

Pulmonx Corp stock is traded at $3.315, with a volume of 351.04K. It is down -9.92% in the last 24 hours and down -36.86% over the past month. Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Previous Close:

$3.68

Open:

$3.73

24h Volume:

351.04K

Relative Volume:

0.88

Market Cap:

$144.12M

Revenue:

$68.68M

Net Income/Loss:

$-60.84M

P/E Ratio:

-2.0719

EPS:

-1.6

Net Cash Flow:

$-38.42M

1W Performance:

-3.63%

1M Performance:

-36.86%

6M Performance:

-50.67%

1Y Performance:

-62.20%

1-Day Range:

$3.31

$3.76

1-Week Range:

$3.31

$3.7908

52-Week Range:

$3.31

$9.405

Pulmonx Corp Stock (LUNG) Company Profile

Name

Pulmonx Corp

Sector

Healthcare (1157)

Industry

Medical Devices (153)

Phone

650-364-0400

Address

700 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

291

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

LUNG's Discussions on Twitter

Compare LUNG with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LUNG Pulmonx Corp	3.315	144.12M	68.68M	-60.84M	-38.42M	-1.60
ABT Abbott Laboratories	129.05	230.70B	42.34B	13.50B	6.66B	7.71
BSX Boston Scientific Corp	102.95	154.22B	17.55B	2.03B	2.72B	1.37
SYK Stryker Corp	387.53	145.74B	23.22B	2.86B	3.58B	7.40
MDT Medtronic Plc	85.11	107.03B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	75.50	44.06B	5.54B	4.18B	623.10M	7.00

Pulmonx Corp Stock (LUNG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-10-25	Initiated	D. Boral Capital	Buy
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Jun-04-24	Initiated	Lake Street	Buy
Feb-23-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-05-23	Initiated	Craig Hallum	Buy
Feb-27-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-03-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-08-21	Upgrade	Piper Sandler	Neutral → Overweight
Apr-01-21	Initiated	Citigroup	Buy
Mar-25-21	Initiated	Piper Sandler	Neutral
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Oct-26-20	Initiated	BofA Securities	Buy
Oct-26-20	Initiated	Canaccord Genuity	Buy
Oct-26-20	Initiated	Morgan Stanley	Equal-Weight
Oct-26-20	Initiated	Stifel	Buy
Oct-26-20	Initiated	Wells Fargo	Equal Weight

View All

Pulmonx Corp Stock (LUNG) Latest News

May 10, 2025

Barclays PLC Sells 27,598 Shares of Pulmonx Co. (NASDAQ:LUNG) - Defense World

May 10, 2025

May 06, 2025

Pulmonx Corporation (NASDAQ:LUNG) Q1 2025 Earnings Call Transcript - Insider Monkey

May 06, 2025

May 05, 2025

Stifel maintains Buy on Pulmonx stock with $16 target By Investing.com - Investing.com Nigeria

May 05, 2025

Stifel maintains Buy on Pulmonx stock with $16 target - Investing.com

May 05, 2025

May 03, 2025

Canaccord Genuity Group Lowers Pulmonx (NASDAQ:LUNG) Price Target to $15.00 - Defense World

May 03, 2025

May 02, 2025

Pulmonx Corp SEC 10-Q Report - TradingView

May 02, 2025

Pulmonx Corp (NASDAQ: LUNG) Loss Of -10.08% Compared To 52-Week Low; YTD Fall -44.48% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel

May 02, 2025